Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human ApoA1 Protein, 50µg  

Recombinant human ApoA1 Protein, 50µg

Recombinant Human Apo-A1 Protein (Human Apo-A1, His Tag) Arg 19 - Gln 267 was produced in human 293 cells (HEK293)

Synonym: recombinant, human, protein, Apolipoprotein A-I, APOA1

More details

AP1-H5225-050

Availability: within 7 days

384,00 €

Background
ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream [1]. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect.[2] Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis.[3] In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin. [4]

Source
Recombinant Human Apo-A1 Protein (Human Apo-A1, His Tag) Arg 19 - Gln 267 (Accession # NP_000030.1) was produced in human 293 cells (HEK293).

Molecular Characterization
rhApoA1, a 250 amino acids protein with polyhistidine tag at C-terminus, and has a calculated MW of 29 kDa. The predicted N-terminus is Asp25. DTT-reduced protein migrates as 26-30 kDa protein.

Endotoxin
Less than 1.0 EU per μg of the rhApoA1 by the LAL method.

Purity
>92% as determined by SDS-PAGE.

Formulation
Refer to data sheet

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
n/a

References

(1) Wasan KM , et al. 2008, Nature Reviews Drug Discovery 7 (1): 84–99.
(2) Yui Y, et al. 1988, J. Clin. Invest. 82 (3): 803–7.
(3) Eggerman, T.L. et al., 1991, J. Lipid Res. 32: 821-828.
(4) Voyiaziakis, E. et al., 1998. J. Lipid Res. 39: 313-321.